George Tziras
Chief Executive Officer bij SMALL PHARMA INC.
Vermogen: 536 025 $ op 31-03-2024
Profiel
George Tziras is currently the Chief Executive Officer & Director at Small Pharma, Inc. He is also a Non-Executive Director at Small Pharma Ltd.
and the Director & Chief Business Officer at Cybin, Inc. Previously, he worked as the Chief Business Officer & Director at Unilock Capital Corp.
Mr. Tziras completed his undergraduate degree at the University of Oxford and his graduate degree at The Paul H.
Nitze School of Advanced International Studies.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
CYBIN, INC.
0.32% | 05-04-2024 | 1 294 747 ( 0.32% ) | 536 025 $ | 31-03-2024 |
Actieve functies van George Tziras
Bedrijven | Functie | Begin |
---|---|---|
SMALL PHARMA INC. | Chief Executive Officer | 20-07-2022 |
CYBIN INC. | Director/Board Member | 23-10-2023 |
Small Pharma Ltd.
Small Pharma Ltd. Pharmaceuticals: MajorHealth Technology Small Pharma Ltd. operates as a pharmaceutical company that develops a rapid-acting antidepressant to treat patients with depression. The company was founded by Peter Rands in 2015 and is headquartered in London, the United Kingdom. | Director/Board Member | 01-01-2015 |
Eerdere bekende functies van George Tziras
Bedrijven | Functie | Einde |
---|---|---|
SMALL PHARMA INC. | Director/Board Member | - |
Opleiding van George Tziras
University of Oxford | Undergraduate Degree |
The Paul H. Nitze School of Advanced International Studies | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
CYBIN INC. | Health Technology |
SMALL PHARMA INC. | Retail Trade |
Bedrijven in privébezit | 2 |
---|---|
Small Pharma Ltd.
Small Pharma Ltd. Pharmaceuticals: MajorHealth Technology Small Pharma Ltd. operates as a pharmaceutical company that develops a rapid-acting antidepressant to treat patients with depression. The company was founded by Peter Rands in 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Unilock Capital Corp.
Unilock Capital Corp. Financial ConglomeratesFinance Unilock Capital Corp. is a development stage company, which engages in the identification and evaluation of assets or businesses with a view to completing a qualifying transaction. It intends to become a capital pool industry. The company was founded on January 23, 2018 and is headquartered in Vancouver, Canada. | Finance |